

# Release of Restricted Securities from Escrow



6 August 2018, Melbourne: In accordance with Listing Rule 3.10A, Rhythm Biosciences Limited (ASX: RHY) advises that the following securities are due to be released from escrow:

| Date of release  | Security Description       | Number    |
|------------------|----------------------------|-----------|
| 29 August 2018   | Ordinary fully paid shares | 7,250,000 |
| 3 September 2018 | Ordinary fully paid shares | 2,500,000 |

**Trevor Lockett**  
Managing Director  
0418 647 490

**Shane Tanner**  
Chairman  
0411 107 099

## ***About Rythym Biosciences***

*Rhythm Biosciences is developing and commercialising Australian medical diagnostics technology for sale across national and international markets.*

*Rhythm's lead product, ColoSTAT™, is intended to provide accurate and early detection of colorectal cancer, acting as either a first-step screening test or within the triage of persons with a positive faecal immunochemical test (FIT) or colonoscopy. As well as being of value to those with risk factors associated with colorectal cancer, ColoSTAT™ provides an alternative for those who choose not to or are unable to be assessed using standard screening programs. Being developed to be an affordable and effective diagnostic, ColoSTAT™ has the potential to play an important role in reducing morbidity, mortality and healthcare costs associated with colorectal cancer.*